Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: brain metastases and warrants further investigation
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
While the current standard of care for most patients involves radiation therapy, the associated side effects have caused clinicians and researchers to search for new treatments with hopefully fewer adverse effects. The growing field of immunotherapy, including immune checkpoint inhibitors, shows promising results in cancer patients with brain metastases and warrants further investigation.
Brain metastases are a common yet dismal complication of metastatic cancers, originating most commonly from nonsmall cell lung cancer, breast cancer, melanoma, and renal cell carcinoma.
APA
Hajdari N, Peereboom DM (2026). Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.. Cancer journal (Sudbury, Mass.), 32(1). https://doi.org/10.1097/PPO.0000000000000806
MLA
Hajdari N, et al.. "Role of Immunotherapy and Targeted Agents to Treat Brain Metastases.." Cancer journal (Sudbury, Mass.), vol. 32, no. 1, 2026.
PMID
41574993 ↗
Abstract 한글 요약
Brain metastases are a common yet dismal complication of metastatic cancers, originating most commonly from nonsmall cell lung cancer, breast cancer, melanoma, and renal cell carcinoma. While the current standard of care for most patients involves radiation therapy, the associated side effects have caused clinicians and researchers to search for new treatments with hopefully fewer adverse effects. The growing field of immunotherapy, including immune checkpoint inhibitors, shows promising results in cancer patients with brain metastases and warrants further investigation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.